Is Hims & Hers Stock in Trouble?
While telehealth has for the most part not been a hot place to invest in, Hims & Hers Health has been the exception to that. Last year, its share price jumped by 172%. And this year, shares have already more than doubled in value (returns as of June 27).
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More »
Recently, however, its share price took a hit amid some troubling news involving Novo Nordisk (NYSE: NVO), the healthcare company behind popular diabetes and weight loss drugs Ozempic and Wegovy. And it raised questions about Hims & Hers' business practices.
Here's what you need to know about these recent developments and whether you should be thinking twice about buying Hims & Hers stock.
A partnership that didn't last all that long
In April, the two companies announced they would collaborate to make it easier for Americans to gain access to effective obesity treatments. Through the Hims & Hers platform, people would be able to obtain Wegovy for $599 per month.
And it seemed as if it would be the start of a promising long-term partnership. Hims & Hers CEO Andrew Dudum said, "We share a vision of what consumer-centered healthcare looks like, and this is just the first step toward delivering that future."
It sounded like a great way for Hims & Hers Health to bring popular drugs onto its platform. And for Novo Nordisk, it would be an opportune way to reach more customers.
Less than two months later, the partnership is over. Novo Nordisk expressed concerns over Hims & Hers marketing practices, which it referred to as "deceptive" and that it "failed to adhere to the law which prohibits mass sales of compounded drugs."
The controversy over compounding
Hims & Hers specializes in selling compounded drugs, which are copies of FDA-approved drugs using adjusted (and unapproved) formulas. They are often made by foreign suppliers and occasionally contain active ingredients that may not be safe. Compounding is used for various appropriate reasons (like certain patients needing a modified version to account for a specific issue) as well as when a drug is in short supply. Among drugmakers, it is considered a controversial practice. Both Wegovy and Ozempic were OK'd for compounding for a time to deal with supply shortages, but that is no longer an issue.
Hims & Hers is justifying the continued use of compounded drugs because it says it offers personalized compounded versions that it says are medically necessary. Novo Nordisk doesn't agree with this practice. Novo Nordisk may have expected that with the partnership, Hims & Hers wouldn't offer compounded versions of its drugs anymore and would instead simply offer the real drugs.
Should Hims & Hers investors be worried?
Hims & Hers has been a growth beast over the years. It went from just $272 million in revenue in 2021 to $1.8 billion in sales over the trailing 12 months. It has also gone from being in the red financially to now generating significant profits; earnings over the past four quarters have totaled $164 million -- more than 9% of its top line.
The business has evolved by offering a wider range of products to its customers, including obesity treatments. But in doing so, it has been pushing the envelope with compounded drugs, and the danger is that patients could experience side effects and consequences that may otherwise not happen with FDA-approved drugs.
My concern is that the business could open itself up to potential legal issues down the road. It is winning over customers by offering low-cost, personalized solutions, but the way it's going about that could lead to significant risk in the future. Plus, if the company ends up having to stop selling compounded drugs, that could thwart its growth prospects.
Hims & Hers has done incredibly well in recent years. But with question marks about its future growth, the potential legal risk ahead, and a high valuation (it trades at more than 70 times its trailing earnings), this isn't a stock I would rush to buy right now.
Should you invest $1,000 in Hims & Hers Health right now?
Before you buy stock in Hims & Hers Health, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Hims & Hers Health wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $722,181!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $968,402!*
Now, it's worth noting Stock Advisor 's total average return is1,069% — a market-crushing outperformance compared to177%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of June 30, 2025
David Jagielski has positions in Novo Nordisk. The Motley Fool has positions in and recommends Hims & Hers Health. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
2 hours ago
- Globe and Mail
Microsoft cutting 9,000 jobs with largest layoff in years
Microsoft MSFT-Q says it is laying off about 9,000 workers, its second mass layoff in months and its largest in more than two years. The tech giant began sending out layoff notices Wednesday that hit the company's Xbox video game business and other divisions. Among those losing their jobs are 830 workers tied to Microsoft's headquarters in Redmond, Washington, according to a notice sent to state officials Wednesday. Microsoft said the cuts will affect multiple teams around the world, including its sales division, part of 'organizational changes' needed to succeed in a 'dynamic marketplace.' The company won't say the total number of layoffs except that it was about 4 per cent of the workforce it had a year ago. A memo to gaming division employees Wednesday from Xbox CEO Phil Spencer said the cuts would position the video game business 'for enduring success and allow us to focus on strategic growth areas.' Xbox would 'follow Microsoft's lead in removing layers of management to increase agility and effectiveness,' Spencer wrote. Microsoft employed 228,000 full-time workers as of June 2024, the last time it reported its annual headcount. Its latest layoffs would cut fewer than 4 per cent of that workforce, according to Microsoft. But it has already had at least three layoffs this year and it's unlikely that new hiring has matched the amount lost. Either way, a 4 per cent cut would amount to somewhere in the range of 9,000 people. Until now, this year's biggest layoff was in May, when Microsoft began laying off about 6,000 workers, nearly 3 per cent of its global workforce and its largest job cuts in more than two years. The cutbacks come as Microsoft continues to invest huge amounts of money in the data centers, specialized computer chips and other infrastructure needed to advance its AI ambitions. The company anticipated those expenses would cost it about US$80-billion in the last fiscal year. Its new fiscal year began Tuesday. Microsoft just last month cut another 300 workers based out of its Redmond headquarters, on top of nearly 2,000 who lost their jobs in the Puget Sound region in May, most of them in software engineering and product management roles, according to information it sent to Washington state employment officials. Microsoft's chief financial officer Amy Hood said on an April earnings call that the company was focused on 'building high-performing teams and increasing our agility by reducing layers with fewer managers.' The company has repeatedly characterized its recent layoffs as part of a push to trim management layers, but the May focus on cutting software engineering jobs has fueled worries about how the company's own AI code-writing products could reduce the number of people needed for programming work. Microsoft CEO Satya Nadella said earlier this year that 'maybe 20, 30 per cent of the code' for some of Microsoft's coding projects 'are probably all written by software.' The latest layoffs, however, seemed centered on slower-growing areas of the company's business, said Wedbush Securities analyst Dan Ives. 'They're focused more and more on AI, cloud and next-generation Microsoft and really looking to cut costs around Xbox and some of the more legacy areas,' Ives said. 'I think they overhired over the years. This is Nadella and team making sure that they're keeping with efficiency and that's the name of the game in Wall Street.' The trimming of the Xbox staff follows Microsoft's years-long expansion of the business surrounding its gaming console, culminating in 2023 with the $75.4-billion acquisition of Activision Blizzard — the California-based maker of hit franchises like Call of Duty and Candy Crush. Before that, in a bid to compete with Sony's PlayStation, it spent $7.5-billion to acquire ZeniMax Media, the parent company of Maryland-based video game publisher Bethesda Softworks. Many of those game studios, which have locations across North America and Europe, were struggling with the layoffs Wednesday, according to social media posts from employees who announced they were looking for new jobs.
CBC
2 hours ago
- CBC
Bay building redevelopment could get $3.4M boost from City of Winnipeg
The redevelopment of the former Hudson's Bay Company building in downtown Winnipeg could get a $3.4-million funding boost from the city. A new report, to be considered by council's executive policy committee next week, calls for funding to make improvements above and below the sidewalks surrounding the building. The Southern Chiefs Organization is in the middle of a $310-million redevelopment of old Hudson's Bay Company building. It's turning the nearly century-old building into a mixed-use development called Wehwehneh Bahgahkinahgohn. The city has already contributed $20.3 million toward the project, including $9.7 million in tax-increment financing and a $10-million grant from the federal housing accelerator fund. Now, city staff recommend giving another $3.4 million in the 2026 budget for streetscaping, including possibly closing a northbound lane of traffic along Memorial Boulevard. Matt Dryburgh, senior manager of economic development and policy, wrote in the report the closure would allow for trees to be planted. "However, further review of the road, land drainage and transit infrastructure considerations are needed to confirm feasibility," Dryburgh wrote. The money would also pay for repairs to areaways — vacant basement spaces that extend out beneath sidewalks. If approved, it would bring the city's total funding to $23.7 million. The funding needs approval from council. The project was originally slated to cost $130 million in 2022, when the Hudson's Bay Company announced the transfer of the six-storey, 655,000-square-foot building at the corner of Portage Avenue and Memorial Boulevard to the SCO, which represents 34 Anishinaabe and Dakota nations in southern Manitoba.
CBC
3 hours ago
- CBC
Automakers push Ottawa to drop EV mandates
Prime Minister Mark Carney met with some of Canada's major automakers on Wednesday to push the government to repeal a mandate requiring all new vehicles to be emissions free by 2035. The meeting happened as Carney tries to land a trade deal with the U.S. by July 21.
